Abstract
Background
Adverse drug reactions and lack of therapeutic efficacy associated with currently prescribed pharmacotherapeutics may be attributed, in part, to inter-individual variability in drug metabolism. Studies on the pharmacogenetics of Cytochrome P450 (CYP) enzymes offer insight into this variability. The objective of this study was to compare the AmpliChip CYP450 Test
®
(AmpliChip) to alternative genotyping platforms for phenotype prediction of CYP2C19 and CYP2D6 in a representative cohort of the South African population.
Methods
AmpliChip was used to screen for thirty-three
CYP2D6
and three
CYP2C19
alleles in two different cohorts. As a comparison cohort 2 was then genotyped using a
CYP2D6
specific long range PCR with sequencing (
CYP2D6
XL-PCR + Sequencing) platform and a PCR-RFLP platform for seven
CYP2C19
alleles.
Results
Even though there was a low success rate for the AmpliChip, allele frequencies for both
CYP2D6
and
CYP2C19
were very similar between the two different cohorts. The
CYP2D6
XL-PCR + Sequencing platform detected
CYP2D6*5
more reliably and could correctly distinguish between
CYP2D6*2
and
*41
in the Black African individuals. Alleles not covered by the AmpliChip were identified and four novel
CYP2D6
alleles were also detected
. CYP2C19
PCR-RFLP identified
CYP2C19*9
,
*15
,
*17
and
*27
in the Black African individuals, with
*2
,
*17
and
*27
being relatively frequent in the cohort. Eliminating mismatches and identifying additional alleles will contribute to improving phenotype prediction for both enzymes. Phenotype prediction differed between platforms for both genes.
Conclusion
Comprehensive genotyping of
CYP2D6
and
CYP2C19
with the platforms used in this study, would be more appropriate than AmpliChip for phenotypic prediction in the South African population. Pharmacogenetically important novel alleles may remain undiscovered when using assays that are designed according to Caucasian specific variation, unless alternate strategies are utilised.